<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="99562"><DrugName>AAV5 RPE65 gene therapy (Leber’s congenital amaurosis), Athena Vision/MeiraGTx</DrugName><DrugSynonyms><Name><Value>AAV5 RPE65 gene therapy (Leber’s congenital amaurosis), Athena Vision</Value></Name><Name><Value>AAV 5.hRPE65</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AAV5 RPE65 gene therapy (Leber’s congenital amaurosis), Athena Vision/MeiraGTx</Value></Name><Name><Value>AAV2/5-OPTIRPE65</Value></Name><Name><Value>A-001, MeiraGTx</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1115426">MeiraGTx UK II Ltd</CompanyOriginator><CompaniesPrimary><Company id="1108651">MeiraGTx</Company><Company id="1115426">MeiraGTx UK II Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1108651" type="Company"><TargetEntity id="5045915944" type="organizationId">Kadmon Gene Therapy Holdings Ltd</TargetEntity></SourceEntity><SourceEntity id="1115426" type="Company"><TargetEntity id="5046736009" type="organizationId">Meiragtx Uk II Ltd</TargetEntity></SourceEntity><SourceEntity id="3448" type="ciIndication"><TargetEntity id="D057130" type="MeSH"></TargetEntity><TargetEntity id="65" type="ORPHANET"></TargetEntity><TargetEntity id="-1563679156" type="omicsDisease"></TargetEntity><TargetEntity id="1529" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="13">Rare Pediatric Disease</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="3448">Lebers congential amaurosis</Indication></IndicationsPrimary><ActionsPrimary><Action id="49590">RPE65 gene stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="15128">Ophthalmological agent</Action><Action id="4781">Adeno-associated virus based gene therapy</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="62">Virus recombinant</Technology><Technology id="620">Ophthalmic formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>S1</Code><Name>OPHTHALMOLOGICALS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-22T13:51:20.000Z</LastModificationDate><ChangeDateLast>2019-05-23T00:00:00.000Z</ChangeDateLast><AddedDate>2015-10-22T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1115426" linkType="Company"&gt;Athena Vision&lt;/ulink&gt; (a start-up company of &lt;ulink linkID="23505" linkType="Company"&gt;University College London&lt;/ulink&gt;) and &lt;ulink linkID="1108651" linkType="Company"&gt;MeiraGTx&lt;/ulink&gt; (formerly Kadmon Gene Therapy) are developing A-001, a gene therapy that delivers the human RPE65 gene  to retinal cells using adeno-associated virus (AAV) vector serotype 2/5 (AAV2/5-OPTIRPE65), for the potential treatment of Leber's congenital amaurosis (LCA) type-2  [&lt;ulink linkID="1704037" linkType="Reference"&gt;1704037&lt;/ulink&gt;], [&lt;ulink linkID="1743631" linkType="Reference"&gt;1743631&lt;/ulink&gt;], [&lt;ulink linkID="1744175" linkType="Reference"&gt;1744175&lt;/ulink&gt;], [&lt;ulink linkID="1766917" linkType="Reference"&gt;1766917&lt;/ulink&gt;], [&lt;ulink linkID="1787697" linkType="Reference"&gt;1787697&lt;/ulink&gt;]. In May 2016, a phase I/II study began [&lt;ulink linkID="1766917" linkType="Reference"&gt;1766917&lt;/ulink&gt;]; by November 2018, dosing was completed in the second quarter of 2018 [&lt;ulink linkID="2093269" linkType="Reference"&gt;2093269&lt;/ulink&gt;]; in May 2019, positive data were reported [&lt;ulink linkID="2151806" linkType="Reference"&gt;2151806&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In May 2019, the company expected to meet with global regulatory authorities in the second half of 2019 to define the development pathway for regulatory approval [&lt;ulink linkID="2151806" linkType="Reference"&gt;2151806&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, the US FDA granted rare pediatric disease designation to A-001 for the treatment of patients with Leber's Congenital Amaurosis [&lt;ulink linkID="1989522" linkType="Reference"&gt;1989522&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, the FDA granted the gene therapy Orphan Drug status for the treatment of LCA [&lt;ulink linkID="1744142" linkType="Reference"&gt;1744142&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In October 2015, the COMP adopted a positive opinion recommending AAV5.hRPE65 for Orphan status for the treatment of LCA [&lt;ulink linkID="1704037" linkType="Reference"&gt;1704037&lt;/ulink&gt;]; in November 2015, Orphan designation was granted [&lt;ulink linkID="1715072" linkType="Reference"&gt;1715072&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In November 2015, a phase I/II dose-escalation trial was planned to be initiated in the first quarter of 2016 [&lt;ulink linkID="1743631" linkType="Reference"&gt;1743631&lt;/ulink&gt;]. In April 2016, an open-label, multicenter, phase I/II dose escalation trial (&lt;ulink linkID="261725" linkType="Protocol"&gt;NCT02781480&lt;/ulink&gt;; 15/0587) of AAV2/5-OPTIRPE65 gene therapy in adults and children (expected n = 27) with retinal dystrophy associated with defects in RPE65 (LCA) was to begin; at that time, the study was to be completed in April 2018. In May 2016, the study was initiated [&lt;ulink linkID="1766917" linkType="Reference"&gt;1766917&lt;/ulink&gt;]. In February 2017, the company completed dosing of the patients in the second cohort [&lt;ulink linkID="1898829" linkType="Reference"&gt;1898829&lt;/ulink&gt;]. In August 2017,seven patients were treated in the trial with the final two patients in the high dose cohort expected to be treated during third quarter of 2017 [&lt;ulink linkID="1956258" linkType="Reference"&gt;1956258&lt;/ulink&gt;]. In October 2017, dosing was completed in all the three dose-escalation cohorts. At that time, dosing was expected to begin in the fourth quarter of 2017 in pediatric patients [&lt;ulink linkID="1971543" linkType="Reference"&gt;1971543&lt;/ulink&gt;]. Later that month, the FDA accepted an IND application for A-001 for pediatric patients in the US. In  November 2017, the first pediatric patient was treated in the UK [&lt;ulink linkID="1989522" linkType="Reference"&gt;1989522&lt;/ulink&gt;]. By November 2018, a total of nine adults had been treated in three escalating dose cohorts and six pediatric patients were treated in the pediatric extension arm of the study. At that time, dosing was completed in the second quarter of 2018 [&lt;ulink linkID="2093269" linkType="Reference"&gt;2093269&lt;/ulink&gt;]. In May 2019, positive data were reported from 15 treated patients (nine adults in three dose escalation cohorts and six pediatric patients in an expansion cohort). Data demonstrated that the trial achieved the primary endpoint of safety and tolerability of AAV-RPE65. Also, observed statistically significant improvement across several secondary endpoints designed to assess clinical activity. At that time, full data were expected later in 2019 [&lt;ulink linkID="2151806" linkType="Reference"&gt;2151806&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2017, a natural history study was ongoing [&lt;ulink linkID="1956258" linkType="Reference"&gt;1956258&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2017, preclinical data were presented at the XXV ESGCT Congress in Berlin, Germany. Data demonstrated that subretinal administration of AAV2/5-OPTIRPE65 compared to AAV2/2 gene therapy in mice showed immune responses against the vector capsid and maximum attainable scotopic responses (~90μV) were achieved with a 300-fold lower titre. Overall the drug was safe and effective [&lt;ulink linkID="1971543" linkType="Reference"&gt;1971543&lt;/ulink&gt;]. Further in vivo data were presented at the same conference. In wild type and RPE65-deficient mice and wild type rabbits, subretinal administration of AAV2/5-OPTIRPE65 did not adversely affect retinal structure or function. In liver, draining lymph nodes and to the tissues of the optic tract, low level vector dissemination was observed without pathological changes in these tissues [&lt;ulink linkID="2000506" linkType="Reference"&gt;2000506&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1115426">MeiraGTx UK II Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3448">Lebers congential amaurosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-05-31T00:00:00.000Z</StatusDate><Source id="1766917" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1108651">MeiraGTx</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3448">Lebers congential amaurosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-05-31T00:00:00.000Z</StatusDate><Source id="1766917" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1108651">MeiraGTx</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3448">Lebers congential amaurosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2107-05-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1115426">MeiraGTx UK II Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3448">Lebers congential amaurosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-13T00:00:00.000Z</StatusDate><Source id="1704037" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1108651">MeiraGTx</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3448">Lebers congential amaurosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-24T00:00:00.000Z</StatusDate><Source id="1743631" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1108651">MeiraGTx</OwnerCompany><Country id="US">US</Country><Indication id="3448">Lebers congential amaurosis</Indication><AwardedIndication>Treatment of Leber congenital amaurosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-10T00:00:00.000Z</MileStoneDate><Source id="1744142" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1115426">MeiraGTx UK II Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="3448">Lebers congential amaurosis</Indication><AwardedIndication>Treatment of Leber’s congenital amaurosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-11T00:00:00.000Z</MileStoneDate><Source id="1715072" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1115426">MeiraGTx UK II Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="3448">Lebers congential amaurosis</Indication><AwardedIndication>Treatment of Leber’s congenital amaurosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-08T00:00:00.000Z</MileStoneDate><Source id="1704037" type="PR"></Source></Row><Row><RegulatoryDesignation id="13">Rare Pediatric Disease</RegulatoryDesignation><OwnerCompany id="1108651">MeiraGTx</OwnerCompany><Country id="US">US</Country><Indication id="3448">Lebers congential amaurosis</Indication><AwardedIndication>Treatment of Leber congenital amaurosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-07T00:00:00.000Z</MileStoneDate><Source id="1989522" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="GTGT-03922"><Name>RPE65 gene</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2151806" linkType="reference" linkID="2151806"&gt;2151806&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1108651">MeiraGTx</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20607">University of London</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="159914" title="MeiraGTx to develop and commercialize UCLB's ocular gene therapy programs worldwide "></Deal></Deals><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>